Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension Using Urine Mass Spectrometry

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-80
SponsorChangi General Hospital

About this trial

* Hypertension is the single largest contributor to cardiovascular disease and death. While adequate control of hypertension reduces risk of disease, many patients have uncontrolled hypertension. This is often due to medication non-adherence. Left undetected, patients are prescribed additional medications, and referred to multiple specialists for investigations - leading to increased healthcare costs. Hence, detecting non-adherence to antihypertensive medications is important. However, patient history, patient recall, or questionnaires, are often inaccurate. Most recently, urine measurements of antihypertensive drug levels, using mass spectrometry, has been established as the gold standard to assess medication adherence. The one-time urine test for medication adherence is ideal: It's convenient, non-invasive, economical, and can be easily performed in a clinic setting. By improving blood pressure control, this will lead to reductions in healthcare visits, avoidance of catastrophic cardiovascular events. Ultimately, this translates to significant economic savings for both patients with hypertension and the healthcare system. * Therefore, the investigators hypothesize that the implementation of urine adherence testing coupled with targeted counselling will improve the adherence and blood pressure control in hypertension. To do this, the investigators aim to (1) evaluate for medication adherence in 312 participants with recent stroke and hypertension; (2) evaluate for medication non-adherence in participants with uncontrolled hypertension; and (3) assess if detection of non-adherence can improve hypertension control.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age of 21 - 80 years

Systolic blood pressure of ≥140 mmHg or average systolic blood pressure ≥135 mmHg, or diastolic blood pressure ≥90 mmHg or average diastolic blood pressure ≥85 mmHg, on at least two measurements

Currently taking 2 or more hypertension medications

Able to provide informed consent.

Disqualifiers

Significant kidney impairment with eGFR of less than 45mL/min/1.73m2 or on dialysis

Known history of chronic liver disease

Trial design

Design model

Single group

Treatments tested in this trial

  • mass spectrometry analysis

    Other intervention

    The collected urine samples will be analyzed to determine medication adherence during study visits

Treatment groups

100 Participants
are divided into 1 treatment group
Group A: mass spectrometry analysisExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in adherence rate

This is the difference in the adherence rates at enrollment and at the end of the study

Time frame
6 months
2

The change in systolic blood pressure

This is the difference in systolic blood pressure between enrollment and the last follow up visit at 6 months

Time frame
6 months
3

The change in diastolic blood pressure

This is the difference in diastolic blood pressure between enrollment and the last follow up visit at 6 months

Time frame
6 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.